Latest filing published 27 Jul 2026 for Opus Genetics, Inc., €19k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Benjamin R. Yerxa discloses dealings in 2 companies, chiefly Opus Genetics, Inc. and Clearside Biomedical, Inc. Between 15 May 2024 and 23 July 2026, the trades on record add up to 7 filings.
In open-market terms, that means 2 purchases worth €19k on one side and 2 sales worth €53k on the other. Netting one side against the other leaves €34k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 3 share grants. 2026 to date brings no purchases and 2 sales.
The record was last updated on 27 July 2026 with an open-market sale (€19k) in Opus Genetics, Inc. The clock since the last published purchase (25 November 2024) now reads 692 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations